{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:31:58Z","timestamp":1792989118859,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Carol Brown, MS, of Prescott Medical Communications Group, Chicago, IL"},{"name":"a contractor of Forest Research Institute"},{"name":"an Allergan affiliate"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.euroneuro.2015.08.020","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T22:39:13Z","timestamp":1441492753000},"page":"1882-1891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II\/III trials"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Durgam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Debelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Zukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2015.08.020_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4088\/JCP.v63n0910","article-title":"Subsyndromal depression is associated with functional impairment in patients with bipolar disorder","volume":"63","author":"Altshuler","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1523\/JNEUROSCI.5074-06.2007","article-title":"Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo","volume":"27","author":"Beaulieu","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s12272-010-1005-8","article-title":"Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors","volume":"33","author":"Cho","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","article-title":"The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO","volume":"66","author":"Graff-Guerrero","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40263-015-0235-1","article-title":"Pharmacotherapy of acute mania: monotherapy or combination therapy with mood stabilizers and antipsychotics?","volume":"29","author":"Grande","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents","volume":"59","author":"Gyerty\u00e1n","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib12","first-page":"489","article-title":"Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments","volume":"7","author":"Jann","year":"2014","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1399-5618.2003.00091.x","article-title":"A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders","volume":"6","author":"Joffe","year":"2004","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","article-title":"Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study","volume":"62","author":"Judd","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archpsyc.65.4.386","article-title":"Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse\/recurrence","volume":"65","author":"Judd","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.4088\/JCP.10m06347yel","article-title":"Bipolar disorder: new perspectives in health care and prevention","volume":"71","author":"Leboyer","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jad.2008.07.006","article-title":"The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD","volume":"114","author":"Marangell","year":"2009","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2015.08.020_bib22","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jad.2007.02.007","article-title":"Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms","volume":"100","author":"McIntyre","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO","volume":"131","author":"Mizrahi","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jad.2010.05.018","article-title":"New treatment guidelines for acute bipolar depression: a systematic review","volume":"129","author":"Nivoli","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.163.2.217","article-title":"Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"163","author":"Perlis","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib27","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib28","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4088\/JCP.10m06523","article-title":"The pharmacologic treatment of bipolar disorder","volume":"72","author":"Sachs","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, Phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","article-title":"Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions","volume":"31","author":"Schwartz","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib32","first-page":"S520","article-title":"Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO","volume":"38","author":"Slifstein","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.bp.105.020321","article-title":"Influence of sub-syndromal symptoms after remission from manic or mixed episodes","volume":"189","author":"Tohen","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1399-5618.2009.00726.x","article-title":"The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders","volume":"11","author":"Tohen","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/acps.12270","article-title":"The bipolar maze: a roadmap through translational psychopathology","volume":"129","author":"Vieta","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rpsm.2015.03.003","article-title":"Personalised medicine applied to mental health: precision psychiatry","volume":"8","author":"Vieta","year":"2015","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jad.2013.12.031","article-title":"Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: results from the IMPACT self-reported online survey","volume":"156","author":"Vieta","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jad.2007.08.007","article-title":"Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission","volume":"107","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 5","key":"10.1016\/j.euroneuro.2015.08.020_bib39","first-page":"S40","article-title":"Atypical antipsychotics in bipolar depression: potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.08.020_bib40","unstructured":"Yatham, L.N., Lu, K., Ruth, A., N\u00e9meth, G., Laszlovszky, I., Earley, W., Durgam, S., 2015. Response and remission rates and number needed to treat with cariprazine in patients with bipolar mania: analyses from 3 phase II\/III trials. In: Proceedings of the 168th Annual Meeting of the American Psychiatric Association. May 16\u201320, Toronto, Canada."},{"key":"10.1016\/j.euroneuro.2015.08.020_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1500276X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1500276X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:36:21Z","timestamp":1668713781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X1500276X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0924977X1500276X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.08.020","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II\/III trials","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP.","name":"copyright","label":"Copyright"}]}}